Galectin Therapeutics Issues Statement Regarding GALTW and GALTU
March 23, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., March 23, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that trading will be...
Galectin Therapeutics to Present at BIO CEO & Investor Conference
February 08, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold...
Galectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders
December 08, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company...
Galectin Therapeutics to Webcast Corporate Presentation at the MicroCap Conference on October 25 in Philadelphia
October 17, 2016 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Oct. 17, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today...
Galectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced Fibrosis
September 27, 2016 16:15 ET
|
Galectin Therapeutics
Larger Phase 2b clinical trial in NASH cirrhosis (NASH-CX) now completely enrolled Closed private placement financing for $1.5 million Conference call to be held today at 5:30 p.m. (Eastern Time) ...
Galectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
August 31, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...
Galectin Therapeutics Announces Completion of Patient Recruitment in its Phase 2 Trial with GR-MD-02 in NASH Patients with Cirrhosis
August 02, 2016 08:45 ET
|
Galectin Therapeutics
NORCROSS, Ga., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer,...